Thursday, 27 January 2022

Australia's most trusted
source of pharma news

Thursday, 27 January 2022

Big week for diabetes drugs

Posted 29 November 2021 AM

Australia's medicines regulator has green-lighted Bayer's Kerendia to delay progression of kidney disease in patients with chronic kidney disease and type 2 diabetes, close to 11 months after it was accepted for evaluation.

It has approved two doses (10 mg and 20 mg) of Kerendia, a non-steroidal mineralocorticoid receptor antagonist (MRA), in addition to standard of care.

To see the whole article, please login

Email this article to a friend

Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.


Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.


Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).


You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.


You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.